PT  - JOURNAL ARTICLE
AU  - Y. Braun-Moscovici
AU  - S. Ben Horin
AU  - A. Dagan
AU  - K. Toledano
AU  - D. Markovits
AU  - A. Saffouri
AU  - R. Beshara
AU  - A. Rozin
AU  - M. A. Nahir
AU  - Y. Chowers
AU  - A. Balbir-Gurman
TI  - FRI0207 The input of measuring of infliximab and adalimumab levels and levels of antibodies to these drugs in the management of patients with autoimmune diseases treated with anti tnf monoclonal antibodies.
AID  - 10.1136/annrheumdis-2013-eular.1334
DP  - 2013 Jun 01
TA  - Annals of the Rheumatic Diseases
PG  - A442--A443
VI  - 72
IP  - Suppl 3
4099  - http://ard.bmj.com/content/72/Suppl_3/A442.3.short
4100  - http://ard.bmj.com/content/72/Suppl_3/A442.3.full
SO  - Ann Rheum Dis2013 Jun 01; 72
AB  - Background In patients (pts) with RA and other autoimmune diseases the immunogenicity during infliximab (INF) or adalimumab (ADA) therapy lead to the r loss of response. Increasing the drug dose or shortening the re-treatment intervals has economical implications. Switching to another biological agent may be suitable. High levels of anti-INF or anti ADA antibodies (Ab) is accompanied by significant reduction in serum drug concentrations. Objectives To assess the input of measuring serum INF and ADA levels and levels of anti-INF-Ab and anti-ADA-Ab in the management of pts with RA and other autoimmune diseases trated with these drugs. Methods Trough serum levels of INF and ADA and anti-INF-Ab and anti-ADA-Ab were measured by ELISA. Anti-INF-Ab were identified by anti-human lambda chain Ab in order to minimize the interference of serum INF. Treated pts were classified into responders and non-responders based on disease activity. Statistics: descriptive statistics, T test, Spearman’s correlation and multiple logistic regression analysis. Results 131 serum tests for INF and 48 - for ADA were performed in 101 pts (mean age 50.2 and disease duration 9.9 years). Among responders 51 pts received INF and 16 pts – ADA. Among non-responders 34 pts had no response and 10 pts losed response ( 24 pts – INF; 20 pts - ADA). Levels (µg/ml, mean, SD) of INF and ADA in responders 4.2(2.3) and 7(5.95) were significantly higher than in non-responders1.09(0.45) and 2.9(0.45) respectively; levels of anti-INF-Ab and anti-ADA-Ab in responders 4.59(1.0) and 0.1(0) were significantly lower than in non-responders 13.13(6.1) and 8.1(1.0). Patients with RA and ankylosing spondylitis had significantly higher Ab levels than pts with psoriatic arthritis: 8.37(3.8), 9.6(0.3) and 3.5(0)µg/ml respectively. High anti-INF-Ab or anti-ADA-Ab levels predicted treatment discontinuation. In all non-responders with low INF/ADA levels and low anti-INF-Ab/anti-ADA-Ab the shortening of re-treatment intervals lead to significant improvement (Table 1). Conclusions Assessment of immunogenicity of anti-TNF monoclonal antibodies proved useful imformation for guiding the therapy in autoimmune diseases with suboptimal clinical response. Patients with low INF/ADA levels and low levels of corresponding Ab may benefit from increasing the drug dose or decreasing of re-treatment intervals. In pts with negligible serum levels of INF/ADA and high levels of corresponding Ab the therapy should be switched to a different drug. Disclosure of Interest: None Declared